In mammals, insulin and insulin-like growth factors (IGFs: IGF1 and IGF2) act through 2 structurally related receptors, the insulin receptor (INSR) and the type 1 IGF receptor (IGF1R), both of which are expressed in developing oocytes. IGF1 plays an important role in female reproduction, and female Igf1 knockout mice fail to ovulate and are infertile. On the other hand, little is known about the in vivo role of the insulin signaling pathway in oocytes during follicular development, although exposure to insulin or IGF1 in vitro improves oocyte maturation. To further address the significance of insulin/IGF signaling, we used conditional mutant mice and ablated the function of the genes encoding INSR, IGF1R, or both receptors specifically in developing mouse oocytes. Our genetic evidence showed unexpectedly that the female reproductive functions are not affected when Insr, Igf1r or both Insr;Igf1r are ablated in oocytes, as the female mice are fertile and exhibit normal estrous cyclicity, oocyte development and maturation, parturition frequency, and litter size. In view of these novel observations indicating that the insulin/IGF signaling is not essential in oocytes, the IGF1-dependent female fertility is re-evaluated and discussed.

Keywords:
Differentiation, Fertility, Growth, Igf1r, Insr Maturation, Mouse, Oozyte
1.
Accili D, Drago J, Lee EJ, Johnson MD, Cool MH, et al: Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. Nat Genet 12:106–109 (1996).
2.
Acevedo N, Ding J, Smith GD: Insulin signaling in mouse oocytes. Biol Reprod 77:872–879 (2007).
3.
Augustin R, Pocar P, Wrenzycki C, Niemann H, Fischer B: Mitogenic and anti-apoptotic activity of insulin on bovine embryos produced in vitro. Reproduction 126:91–99 (2003).
4.
Baker J, Liu JP, Robertson EJ, Efstratiadis A: Role of insulin-like growth factors in embryonic and postnatal growth. Cell 75:73–82 (1993).
5.
Baker J, Hardy MP, Zhou J, Bondy C, Lupu F, et al: Effects of an Igf1 gene null mutation on mouse reproduction. Mol Endocrinol 10:903–918 (1996).
6.
Bohni R, Riesgo-Escovar J, Oldham S, Brogiolo W, Stocker H, et al: Autonomous control of cell and organ size by CHICO, a Drosophila homolog of vertebrate IRS1–4. Cell 97:865–875 (1999).
7.
Brogiolo W, Stocker H, Ikeya T, Rintelen F, Fernandez R, Hafen E: An evolutionarily conserved function of the Drosophila insulin receptor and insulin-like peptides in growth control. Curr Biol 11:213–221 (2001).
8.
Bruning JC, Michael MD, Winnay JN, Hayashi T, Horsch D, et al: A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell 2:559–569 (1998).
9.
Bruning JC, Gautam D, Burks DJ, Gillette J, Schubert M, et al: Role of brain insulin receptor in control of body weight and reproduction. Science 289:2122–2125 (2000).
10.
Cara JF, Rosenfield RL: Insulin-like growth factor I and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells. Endocrinology 123:733–739 (1988).
11.
Castrillon DH, Miao L, Kollipara R, Horner JW, DePinho RA: Suppression of ovarian follicle activation in mice by the transcription factor Foxo3a. Science 301:215–218 (2003).
12.
Cederroth CR, Schaad O, Descombes P, Chambon P, Vassalli JD, Nef S: Estrogen receptor alpha is a major contributor to estrogen-mediated fetal testis dysgenesis and cryptorchidism. Endocrinology 148:5507–5519 (2007).
13.
Chandrashekar V, Zaczek D, Bartke A: The consequences of altered somatotropic system on reproduction. Biol Reprod 71:17–27 (2004).
14.
Dietrich P, Dragatsis I, Xuan S, Zeitlin S, Efstratiadis A: Conditional mutagenesis in mice with heat shock promoter-driven Cre transgenes. Mamm Genome 11:196–205 (2000).
15.
Dupont J, Holzenberger M: Biology of insulin-like growth factors in development. Birth Defects Res C Embryo Today 69:257–271 (2003).
16.
Efstratiadis A: Genetics of mouse growth. Int J Dev Biol 42:955–976 (1998).
17.
Eppig JJ: Oocyte control of ovarian follicular development and function in mammals. Reproduction 122:829–838 (2001).
18.
Fan HY, Liu Z, Cahill N, Richards JS: Targeted disruption of Pten in ovarian granulosa cells enhances ovulation and extends the life span of luteal cells. Mol Endocrinol 22:2128–2140 (2008).
19.
Gomez E, Tarin JJ, Pellicer A: Oocyte maturation in humans: the role of gonadotropins and growth factors. Fertil Steril 60:40–46 (1993).
20.
Granelli-Piperno A, Reich E: A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med 148:223–234 (1978).
21.
Huarte J, Belin D, Vassalli JD: Plasminogen activator in mouse and rat oocytes: induction during meiotic maturation. Cell 43:551–558 (1985).
22.
Joshi RL, Lamothe B, Cordonnier N, Mesbah K, Monthioux E, et al: Targeted disruption of the insulin receptor gene in the mouse results in neonatal lethality. EMBO J 15:1542–1547 (1996).
23.
Kadakia R, Arraztoa JA, Bondy C, Zhou J: Granulosa cell proliferation is impaired in the Igf1 null ovary. Growth Horm IGF Res 11:220–224 (2001).
24.
Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685 (1970).
25.
Lan ZJ, Xu X, Cooney AJ: Differential oocyte-specific expression of Cre recombinase activity in GDF-9-iCre, Zp3cre, and Msx2cre transgenic mice. Biol Reprod 71:1469–1474 (2004).
26.
Levy MJ, Hernandez ER, Adashi EY, Stillman RJ, Roberts CT Jr, LeRoith D: Expression of the insulin-like growth factor (IGF)-I and -II and the IGF-I and -II receptor genes during postnatal development of the rat ovary. Endocrinology 131:1202–1206 (1992).
27.
Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A: Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 Igf receptor (Igf1r). Cell 75:59–72 (1993).
28.
Louvi A, Accili D, Efstratiadis A: Growth-promoting interaction of IGF-II with the insulin receptor during mouse embryonic development. Dev Biol 189:33–48 (1997).
29.
Ludwig T, Eggenschwiler J, Fisher P, D’Ercole AJ, Davenport ML, Efstratiadis A: Mouse mutants lacking the type 2 IGF receptor (IGF2R) are rescued from perinatal lethality in Igf2 and Igf1r null backgrounds. Dev Biol 177:517–535 (1996).
30.
Nef S, Verma-Kurvari S, Merenmies J, Vassalli JD, Efstratiadis A, et al: Testis determination requires insulin receptor family function in mice. Nature 426:291–295 (2003).
31.
Nelson JF, Felicio LS, Randall PK, Sims C, Finch CE: A longitudinal study of estrous cyclicity in aging C57BL/6J mice: I. Cycle frequency, length and vaginal cytology. Biol Reprod 27:327–339 (1982).
32.
Papaioannou MD, Pitetti JL, Ro S, Park C, Aubry F, et al: Sertoli cell dicer is essential for spermatogenesis in mice. Dev Biol 326:250–259 (2009).
33.
Pedersen T, Peters H: Proposal for a classification of oocytes and follicles in the mouse ovary. J Reprod Fertil 17:555–557 (1968).
34.
Reddy P, Liu L, Adhikari D, Jagarlamudi K, Rajareddy S, et al: Oocyte-specific deletion of Pten causes premature activation of the primordial follicle pool. Science 319:611–613 (2008).
35.
Sakaguchi M, Dominko T, Yamauchi N, Leibfried-Rutledge ML, Nagai T, First NL: Possible mechanism for acceleration of meiotic progression of bovine follicular oocytes by growth factors in vitro. Reproduction 123:135–142 (2002).
36.
Samoto T, Maruo T, Ladines-Llave CA, Matsuo H, Deguchi J, et al: Insulin receptor expression in follicular and stromal compartments of the human ovary over the course of follicular growth, regression and atresia. Endocr J 40:715–726 (1993).
37.
Soriano P: Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet 21:70–71 (1999).
38.
Stefanello JR, Barreta MH, Porciuncula PM, Arruda JN, Oliveira JF, et al: Effect of angiotensin II with follicle cells and insulin-like growth factor-I or insulin on bovine oocyte maturation and embryo development. Theriogenology 66:2068–2076 (2006).
39.
Stratikopoulos E, Szabolcs M, Dragatsis I, Klinakis A, Efstratiadis A: The hormonal action of IGF1 in postnatal mouse growth. Proc Natl Acad Sci USA 105:19378–19383 (2008).
40.
Stutz A, Conne B, Huarte J, Gubler P, Volkel V, et al: Masking, unmasking, and regulated polyadenylation cooperate in the translational control of a dormant mRNA in mouse oocytes. Genes Dev 12:2535–2548 (1998).
41.
van den Hurk R, Zhao J: Formation of mammalian oocytes and their growth, differentiation and maturation within ovarian follicles. Theriogenology 63:1717–1751 (2005).
42.
Vassalli JD, Dayer JM, Wohlwend A, Belin D: Concomitant secretion of prourokinase and of a plasminogen activator-specific inhibitor by cultured human monocytes-macrophages. J Exp Med 159:1653–1668 (1984).
43.
Xuan S, Kitamura T, Nakae J, Politi K, Kido Y, et al: Defective insulin secretion in pancreatic beta cells lacking type 1 IGF receptor. J Clin Invest 110:1011–1019 (2002).
44.
Zhou J, Bondy C: Anatomy of the human ovarian insulin-like growth factor system. Biol Reprod 48:467–482 (1993).
45.
Zhou J, Chin E, Bondy C: Cellular pattern of insulin-like growth factor-I (IGF-I) and IGF-I receptor gene expression in the developing and mature ovarian follicle. Endocrinology 129:3281–3288 (1991).
46.
Zhou J, Kumar TR, Matzuk MM, Bondy C: Insulin-like growth factor I regulates gonadotropin responsiveness in the murine ovary. Mol Endocrinol 11:1924–1933 (1997).
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.